Joseph JD - Phathom Pharmaceuticals Chief Officer

Phathom Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.5767) % which means that it has lost $0.5767 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 2.91 in 2024, whereas Return On Tangible Assets are likely to drop (0.51) in 2024. At this time, Phathom Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 325 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 26.7 M in 2024.

Similar Executives

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. Phathom Pharmaceuticals (PHAT) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Florham Park, NJ, United States, 07932 and employs 452 people. Phathom Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Phathom Pharmaceuticals Leadership Team

Phathom Stock Performance Indicators

Additional Tools for Phathom Stock Analysis